No Data
SymBio Pharmaceuticals: Revised Extraordinary Report
Synbio Pharmaceuticals' shareholding in Cantor Fitzgerald has risen to 13.68%.
It has been revealed that the shareholding percentage of Cantor Fitzgerald in Synlogic Pharmaceuticals <4582.T> has increased. According to the large shareholding change report submitted by Cantor Fitzgerald after the market close on the 16th, the shareholding percentage rose from 7.44% at the time of the last report to 13.68%. The purpose of the shareholding is for pure investment. The closing price on the 16th was 151 yen, down 3 yen from the previous day. Provided by Wealth Advisor Co.
Express News | [Change Report] CANTOR FITZGERALD reports that the Shareholding ratio of Symbio Pharmaceuticals (4582.JP) has increased to 13.68%.
SymBio Pharmaceuticals --- Business plan and growth potential.
On the 31st, Symphony Pharma <4582> announced matters related to its business plan and growth potential. For the fiscal year ending December 2024, steady progress was made in the treatment areas of hematopoietic stem cell transplantation, hematologic tumors, solid tumors, and neurodegenerative diseases. In terms of performance, revenue reached 2.452 billion yen, affected by the penetration of generic Pharmaceuticals, price reductions, and usage restrictions due to infection control measures. The gross profit was 1.873 billion yen, with a profit margin of 76.4%, a decrease from the previous year. Selling expenses and general administration.
Station Investigation, Value C and others [Emerging Markets Press Release]
＜3646＞ Station exploration performance estimate revision, this period's operating profit forecast is 0.103 billion yen, revised from 0.101 billion yen. ＜4582＞ Symbio Pharmaceuticals issued the 7th unsecured Convertible Bonds with subscription rights (number of potential Stocks is 3.8 million, and the funds raised are approximately 0.6 billion yen). ＜4586＞ Medrek de Western Therapeutics is co-developing the MRX-5LBT approval application in the USA. ＜9211＞ F-Code's acquisition of treasury shares has ended. ＜9238＞ Value C Digital Plus ＜3691>
SymBio Pharmaceuticals: Extraordinary Report
